{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:17Z","timestamp":1792831037663,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["ORF-2026-1049"],"award-info":[{"award-number":["ORF-2026-1049"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110574","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:16:32Z","timestamp":1790262992000},"page":"110574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties"],"prefix":"10.1016","volume":"183","author":[{"given":"Abdelrahman","family":"Hamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Salih","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahed Nasser Eid","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa I.","family":"Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"El-Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem A.","family":"Ghabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nareman A.","family":"Nawareg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed W.","family":"El-Shafey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.-M.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110574_bb0005","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110574_bb0010","doi-asserted-by":"crossref","first-page":"1794130","DOI":"10.3389\/fimmu.2026.1794130","article-title":"Multidimensional tumor heterogeneity and its role in therapeutic resistance","volume":"17","author":"Mubin","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cells14060403","article-title":"Cross-talk between cancer and its cellular environment-a role in cancer progression","volume":"14","author":"Turlej","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110574_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110574_bb0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110574_bb0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110574_bb0035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","article-title":"Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy","volume":"15","author":"Joshi","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0040","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110574_bb0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110574_bb0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ejca.2006.01.005","article-title":"Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?","volume":"42","author":"Assenat","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110574_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122954","article-title":"Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment","volume":"315","author":"Huang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2026.110574_bb0060","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2013.10.013","article-title":"Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now","volume":"345","author":"Qiao","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110574_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102673","article-title":"Inflammation-induced DNA damage, mutations and cancer","volume":"83","author":"Kay","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bioorg.2026.110574_bb0070","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/1078-0432.CCR-09-0788","article-title":"Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward","volume":"16","author":"Menter","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110574_bb0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.prostaglandins.2011.08.005","article-title":"COX-2 and PGE2-dependent immunomodulation in breast cancer","volume":"96","author":"Chen","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.bioorg.2026.110574_bb0080","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.7150\/ijms.44439","article-title":"The role of Cyclooxygenase-2 in colorectal cancer","volume":"17","author":"Sheng","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bioorg.2026.110574_bb0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.32010","article-title":"Cyclooxygenase-2 in gastrointestinal malignancies","volume":"125","author":"Nagaraju","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110574_bb0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2013.01.012","article-title":"Cox-2 in non-small cell lung cancer: a meta-analysis","volume":"419","author":"Jiang","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bioorg.2026.110574_bb0095","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12032-010-9519-y","article-title":"Clinical significance of cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)","volume":"28","author":"Yang","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0100","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.3748\/wjg.v20.i31.10729","article-title":"Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase","volume":"20","author":"Knab","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.bioorg.2026.110574_bb0105","doi-asserted-by":"crossref","first-page":"10997","DOI":"10.1007\/s11033-012-2001-5","article-title":"Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer","volume":"39","author":"Shao","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2026.110574_bb0110","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.oraloncology.2009.03.016","article-title":"An overview on the expression of cyclooxygenase-2 in tumors of the head and neck","volume":"45","author":"Mendes","year":"2009","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/2211552802999140131105947","article-title":"The influence of Cox-2 and bioactive lipids on hematological cancers","volume":"2","author":"Ramon","year":"2013","journal-title":"Curr. Angiogen."},{"key":"10.1016\/j.bioorg.2026.110574_bb0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2026.110574_bb0125","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1039\/D5MD00196J","article-title":"Recent advances in targeting COX-2 for cancer therapy: a review","volume":"16","author":"Kassab","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637504","article-title":"Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer","volume":"11","author":"Pu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118781","article-title":"Kumar, COX-2 inhibitors in inflammation and cancer: recent developments in medicinal chemistry","volume":"310","author":"Chahat","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0140","first-page":"9010","article-title":"Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0145","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1158\/0008-5472.CAN-07-0141","article-title":"EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1\/Sp3 transcription factors in human gliomas","volume":"67","author":"Xu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110574_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110574_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110574_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110389","article-title":"Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: recent advancement","volume":"129","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110574_bb0165","article-title":"Combined inhibition of epidermal growth factor receptor and Cyclooxygenase-2 as a novel approach to enhance radiotherapy","volume":"1","author":"Fu","year":"2011","journal-title":"J. Cell Sci. Ther."},{"key":"10.1016\/j.bioorg.2026.110574_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1479-666X(09)80042-5","article-title":"COX-2, VEGF and tumour angiogenesis","volume":"7","author":"Toomey","year":"2009","journal-title":"Surgeon"},{"key":"10.1016\/j.bioorg.2026.110574_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0180","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3748\/wjg.v11.i24.3724","article-title":"Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma","volume":"11","author":"Zhi","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0185","article-title":"Improving VEGF-targeted therapies through inhibition of COX-2\/PGE2 signaling","volume":"1","author":"Xu","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0190","doi-asserted-by":"crossref","first-page":"242ra284","DOI":"10.1126\/scitranslmed.3008455","article-title":"COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models","volume":"6","author":"Xu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110574_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bjc.2012.591","article-title":"Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts","volume":"108","author":"Wang","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110574_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107951","article-title":"Harnessing potential COX-2 engagement for boosting anticancer activity of substituted 2-mercapto-4(3H)-quinazolinones with promising EGFR\/VEGFR-2 inhibitory activities","volume":"153","author":"Hamdi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109162","article-title":"Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition","volume":"166","author":"Serag","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131363","article-title":"Simultaneous inhibition of EGFR\/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells","volume":"10","author":"Valverde","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110574_bb0215","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ejmech.2014.07.044","article-title":"A review on anticancer potential of bioactive heterocycle quinoline","volume":"97","author":"Afzal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0220","series-title":"Profile of Neratinib and its Potential in the Treatment of Breast Cancer","first-page":"147","author":"Feldinger","year":"2015"},{"key":"10.1016\/j.bioorg.2026.110574_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2013.06.030","article-title":"Liquid chromatography\u2013tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma","volume":"934","author":"Luethi","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.bioorg.2026.110574_bb0230","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/1078-0432.CCR-10-3387","article-title":"Foretinib (GSK1363089), an orally available multikinase inhibitor of c-met and VEGFR-2, blocks proliferation, induces Anoikis, and impairs ovarian cancer metastasis","volume":"17","author":"Zillhardt","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110574_bb0235","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.bioorg.2026.110574_bb0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11060-016-2332-5","article-title":"Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma","volume":"131","author":"Kalpathy-Cramer","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0245","doi-asserted-by":"crossref","first-page":"32978","DOI":"10.1039\/D4RA06394E","article-title":"Design, synthesis, and biological evaluation of novel quinoline-based EGFR\/HER-2 dual-target inhibitors as potential anti-tumor agents","volume":"14","author":"Al-Wahaibi","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110574_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.07.042","article-title":"Design, synthesis and anticancer evaluation of new substituted Thiophene-Quinoline derivatives","volume":"27","author":"Othman","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272362","article-title":"Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway","volume":"17","author":"Taghour","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110574_bb0260","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bmcl.2011.12.017","article-title":"Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase","volume":"22","author":"Rizvi","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110574_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccmp.2023.100102","article-title":"Clinical use of COX-2 inhibitors containing Quinoline heterocycle as a selective therapeutic agents for complementary medicine","volume":"3","author":"Ambatkar","year":"2023","journal-title":"Clin. Complement. Med. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110574_bb0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s43094-025-00821-7","article-title":"Current progress in synthetic and medicinal chemistry of pyrazole hybrids as potent anticancer agents with SAR studies","volume":"11","author":"Nehra","year":"2025","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110574_bb0275","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s11030-024-10906-9","article-title":"Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation","volume":"29","author":"Ghoneim","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110574_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2025.100227","article-title":"Synthetic advances and SAR insights of pyrazole-based VEGFR-2 kinase inhibitors","volume":"28","author":"Wanode","year":"2025","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110574_bb0285","first-page":"2011","article-title":"Pyrazole: an emerging privileged scaffold in drug discovery, future","volume":"15","author":"Alam","year":"2023","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109444","article-title":"Pyrazole derivatives as dual COX-2\/EGFR inhibitors with anticancer potential: optimization of difenamizole analogs","volume":"170","author":"Farag","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0295","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bioorg.2018.03.023","article-title":"Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2\/\u22125-LOX inhibition profile of some novel quinoline derivatives","volume":"78","author":"Chaaban","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0300","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bioorg.2018.10.038","article-title":"Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors","volume":"83","author":"George","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0305","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1002\/slct.202102917","article-title":"Dual kinase inhibition of EGFR\/HER2: design, synthesis and molecular docking of thiazolylpyrazolyl-based aminoquinoline derivatives as anticancer agents","volume":"6","author":"Batran","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110574_bb0310","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70256","article-title":"New Antiproliferative Pyrazole\/Quinoline hybrids: design, synthesis, and biological evaluation as EGFR inhibitors","volume":"107","author":"Shoman","year":"2026","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2026.110574_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108182","article-title":"New molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers","volume":"156","author":"Ismail","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107403","article-title":"Discovery of novel pyrazole based urea\/Thiourea derivatives as multiple targeting VEGFR-2, EGFRWT, EGFRT790M tyrosine kinases and COX-2 inhibitors, with anti-cancer and anti-inflammatory activities","volume":"147","author":"Fadaly","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0325","doi-asserted-by":"crossref","first-page":"17446","DOI":"10.1021\/acsomega.3c00692","article-title":"Design and development of COX-II inhibitors: current scenario and future perspective, ACS","volume":"8","author":"Chahal","year":"2023","journal-title":"Omega"},{"key":"10.1016\/j.bioorg.2026.110574_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138634","article-title":"Synthesis, anti-inflammatory, antibacterial, and antioxidant evaluation of novel pyrazole-linked hydrazone derivatives","volume":"1312","author":"Kamat","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110574_bb0335","article-title":"Exploring Quinoline-linked Chalcones as broad-Spectrum antimicrobial agents: synthesis, antibacterial, antifungal, molecular docking, pharmacokinetics, and DFT investigation","volume":"109389","author":"Tidke","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103987","article-title":"Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: promising antibreast cancer agent","volume":"101","author":"El-Shafey","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0345","doi-asserted-by":"crossref","first-page":"11683","DOI":"10.3390\/molecules181011683","article-title":"Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives","volume":"18","author":"Lopes","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110574_bb0350","first-page":"339","article-title":"Conformational study on N-acylhydrazones of aromatic-aldehydes by nmr-spectroscopy, in, SOC CHIMICA ITALIANA VIALE LIEGI 48, I-00198 ROME","author":"Palla","year":"1982","journal-title":"ITALY"},{"key":"10.1016\/j.bioorg.2026.110574_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.110574_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.110574_bb0365","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/genes13122183","article-title":"Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Nishihara","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.110574_bb0370","article-title":"Control of cell metabolism by the epidermal growth factor receptor, Biochimica et Biophysica Acta (BBA) - molecular","volume":"1869","author":"Orofiamma","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.110574_bb0375","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1054\/bjoc.2001.1876","article-title":"Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells","volume":"85","author":"Pidgeon","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110574_bb0380","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.xphs.2016.12.002","article-title":"Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options","volume":"106","author":"Aungst","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110574_bb0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.110574_bb0390","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0395","doi-asserted-by":"crossref","first-page":"21079","DOI":"10.1039\/D5RA09370H","article-title":"Discovery of thieno[2,3-d]pyrimidine-based dual Aurora B\/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model","volume":"16","author":"El-Shafey","year":"2026","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110574_bb0400","doi-asserted-by":"crossref","DOI":"10.1007\/s11030-026-11543-0","article-title":"Quinazoline-sulfonamide hybrids as multitarget anticancer agents: inhibition of carbonic anhydrase IX\/XII isoforms and VEGFR-2 with in vitro and in silico validation","author":"Zeidan","year":"2026","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110574_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2026.118766","article-title":"Novel benzofuran\u20131,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2\/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies","volume":"142","author":"Serag","year":"2026","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108526","article-title":"Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: mechanistic insights from apoptosis and cell cycle modulation","volume":"161","author":"El-Shafey","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0415","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14756366.2022.2062752","article-title":"Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers","volume":"37","author":"Elzahabi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107234","article-title":"New 2-oxoindole derivatives as multiple PDGFR\u03b1\/\u00df and VEGFR-2 tyrosine kinase inhibitors","volume":"145","author":"Ezelarab","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2026.147358","article-title":"Novel iminophosphorane derivatives as dual carbonic anhydrase and COX-2 inhibitors with potent anti-breast cancer activity","volume":"1380","author":"El-Shanawany","year":"2027","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110574_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109846","article-title":"Click chemistry synthesis of triazole-grafted quinazolinones as new multi-panel anticancer agents: mechanistic insights into apoptosis and cell cycle arrest in colorectal cancer","volume":"176","author":"Al-Sanea","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0435","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.2147\/DDDT.S490930","article-title":"Design, synthesis, pharmacological evaluation of Quinazolin-4(3H)-ones bearing urea functionality as potential VEGFR-2 inhibitors","volume":"18","author":"Al-Sanea","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2026.110574_bb0440","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.3390\/ijms23169442","article-title":"Augmented therapeutic potential of EC-synthetic Retinoids in Caco-2 cancer cells using an in vitro approach","volume":"23","author":"Abdelaal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110574_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127281","article-title":"Quinazoline based HSP90 inhibitors: synthesis, modeling study and ADME calculations towards breast cancer targeting","volume":"30","author":"El-Shafey","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110574_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109263","article-title":"New 2-benzylideneamino-4,5-diphenylfuran-3-carbonitrile derivatives and their benzylamino analogues: synthesis, in vitro cytotoxicity, protein kinase inhibitory activity and in silico insights","volume":"168","author":"Osman","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0455","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110574_bb0460","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1021\/acsmedchemlett.0c00395","article-title":"Spiroindoline-capped selective hdac6 inhibitors: design, synthesis, structural analysis, and biological evaluation","volume":"11","author":"Saraswati","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110574_bb0465","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejmech.2018.11.004","article-title":"Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents","volume":"162","author":"Brindisi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0470","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1039\/C9FO00265K","article-title":"Dietary polyphenols rutin, taxifolin and quercetin related compounds target Leishmania amazonensis arginase","volume":"10","author":"da Silva","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2026.110574_bb0475","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejmech.2017.04.057","article-title":"Structural characterization of giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX","volume":"135","author":"Brogi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0480","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0485","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cmdc.201700759","article-title":"Development of potent inhibitors of the Mycobacterium tuberculosis virulence factor Zmp1 and evaluation of their effect on mycobacterial survival inside macrophages","volume":"13","author":"Paolino","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110574_bb0490","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fchem.2019.00574","article-title":"Identification of novel 3-Hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach","volume":"7","author":"Sirous","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0495","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1039\/D0FO01511C","article-title":"Amyloid \u03b2 fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil","volume":"11","author":"Brogi","year":"2020","journal-title":"Food Funct."},{"key":"10.1016\/j.bioorg.2026.110574_bb0500","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1021\/j100078a035","article-title":"A multiple-time-step molecular dynamics algorithm for macromolecules","volume":"98","author":"Humphreys","year":"1994","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.bioorg.2026.110574_bb0505","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A"},{"key":"10.1016\/j.bioorg.2026.110574_bb0510","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1063\/1.467468","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.110574_bb0515","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:11Z","timestamp":1792828751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":103,"alternative-id":["S0045206826011107"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110574","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110574"}}